面向多周期癌症治疗的高效时间-事件剂量递增指导
文章指出,随着癌症治疗从化疗、靶向治疗发展到免疫治疗和嵌合抗原受体T细胞,早期I期试验仍主要采用剂量递增设计,且多仅监测第一治疗周期的安全性。作者提出多周期时间-事件模型(TITE-CLRM:时间间隔-事件互补对数-对数回归模型),作为过量控制递增原则的扩展,用于指导多周期治疗的剂量递增试验,并通过模拟研究进行评价。
要点
- 早期I期肿瘤试验仍以剂量递增设计为主,通常仅监测第一周期安全性。
- 多周期治疗中,毒性可出现在第一周期之后,仅关注第一周期成为局限。
- 作者提出TITE-CLRM多周期时间-事件模型,扩展过量控制递增原则。
核心结论
- 作者提出多周期时间-事件模型(TITE-CLRM),用于指导多周期治疗的剂量递增试验,平衡较长治疗期的安全监测与患者持续安全入组的需求。
研究设计与样本
- 文章为方法学论文,提出TITE-CLRM模型,作为过量控制递增原则等已有概念的扩展,并以当前药物开发项目为动机,通过模拟研究进行评价。
主要发现
- 多周期治疗中毒性可出现在第一周期之后,仅监测第一治疗周期成为当前多周期治疗疗法的局限。
- TITE-CLRM模型可指导多周期治疗的剂量递增试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of cancer has rapidly evolved over time in quite dramatic ways, for example, from chemotherapies, targeted therapies to immunotherapies and chimeric antigen receptor T-cells. Nonetheless, the basic design of early phase I trials in oncology still follows predominantly a dose-escalation design. These trials monitor safety over the first treatment cycle to escalate the dose of the investigated drug. However, over time, studying additional factors such as drug combinations and/or variation in the timing of dosing became important as well. Existing designs were continuously enhanced and expanded to account for increased trial complexity. With toxicities occurring at later stages beyond the first cycle and the need to treat patients over multiple cycles, the focus on the first treatment cycle only is becoming a limitation in nowadays multi-cycle treatment therapies. Here, we introduce a multi-cycle time-to-event model (TITE-CLRM: Time-Interval-To-Event Complementary-Loglog Regression Model), allowing guidance of dose-escalation trials studying multi-cycle therapies. The challenge lies in balancing the need to monitor the safety of longer treatment periods with the need to continuously enroll patients safely. The proposed multi-cycle time-to-event model is formulated as an extension to established concepts like the escalation with overdose control principle. The model is motivated by a current drug development project and evaluated in a simulation study.
引用
- Widmer LA, Weber S, Xu Y, et al. Towards Efficient Time-to-Event Dose-Escalation Guidance of Multi-Cycle Cancer Therapies. Stat Med. 2025. PMID: 40956065. doi:10.1002/sim.70229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。